Subscribe to Search results

Anti-HBc testing came to be regarded, and argued over, as the most likely surrogate test as the epidemiological pattern of AIDS was considered to be similar to that of Hepatitis B.

Published on:

Recommendations by the National Hemophilia Foundation's Medical and Scientific Advisory Committee were for the "Evaluation and implementation (if verified) of surrogate laboratory tests that would identify individuals at high risk of AIDS transmission."

Published on:

Dr Ojala of Cutter sent a memo to Whilhelm Schaeffler noting that the time had come for hepatitis core anti-body testing for plasma.

Published on:

The Hepatitis B Core Antibody Testing Group published an interim report in March 1984 and a full report in July 1984, and deemed that testing was not necessary.

Published on:

Of the 11 Biological Management Committee members, 3 voted in favour of anti-HBc testing, 1 abstained and 7 voted against it.

Published on:

Cutter introduced its own programme of mandatory anti-HBc surrogate testing.

Published on:

Biological Management Committee members outlined the perceived advantages and disadvantages of anti-HBc testing in a meeting.

Published on:

Alpha's AIDS Task Force considered what to do with 11 plasma donations from a donor in Dallas who "possibly" had "some AIDS symptoms". The task force decided to release four lots of factor concentrate containing his plasma but not to use any plasma from the donor that had not yet been pooled.

Published on:

Cutter stated that while it had not had to make any decisions about the disposition of a lot of Koate from a donor who developed AIDS, any decision would subsequently depend on a number of factors.

Published on:

Dr Ojala of Cutter sent a memo to Wilhelm Schaeffler to discuss a review of possible courses of action where donors with AIDS were discovered to have donated to plasma pools.

Published on:

At the request of the FDA, representatives of the fractionators met FDA officials to discuss the approach to be taken to future recall of products.

Published on:

Following the first withdrawal of products by Hyland the National Hemophilia Foundation had continued to urge its members to use factor concentrates.

Published on:

The National Hemophilia Foundation restated its original position statement that products should be automatically recalled where a donor was diagnosed with AIDS or characteristics strongly suggestive of AIDS.

Published on:

The minutes of a meeting held at NIBSC highlighted that the issue of withdrawal was not approached purely as a scientific one, but as a question of policy that took into account concerns pertaining to economics and the perceived need to maintain the supply of fractionated blood products.

Published on:

Patient information leaflets became a legal requirement in the UK for all medicines.

Published on:

Cutter confirmed that all plasma was being collected from FDA licensed and inspected centres.

Published on:

William Srigley of Cutter Pharmaceutical gave evidence that he was aware before July 1982 that a homosexual donor who was hepatitis positive risked transmitting AIDS.

Published on:

The evidence is that after February 1983 any remaining stocks of factor concentrates that had been prepared by Cutter using prison plasma were used for research and development purposes only.

Published on:

"The New England Journal of Medicine", published an article by Gottlieb et al titled "Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men".

Published on:

The New England Journal of Medicine published an article by Masur et al titled "An outbreak of community-acquired pneumocystis carinii pneumonia".

Published on: